- Home
- ACRV vs ACTU Comparison
ACRV vs ACTU Comparison
Compare ACRV & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- ACTU
- Stock Information
- Founded
- ACRV 2018
- ACTU 2015
- Country
- ACRV United States
- ACTU United States
- Employees
- ACRV N/A
- ACTU N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- ACTU
- Sector
- ACRV Health Care
- ACTU
- Exchange
- ACRV Nasdaq
- ACTU NYSE
- Market Cap
- ACRV 59.9M
- ACTU 135.0M
- IPO Year
- ACRV 2022
- ACTU 2024
- Fundamental
- Price
- ACRV $1.18
- ACTU $9.90
- Analyst Decision
- ACRV Strong Buy
- ACTU Strong Buy
- Analyst Count
- ACRV 5
- ACTU 1
- Target Price
- ACRV $19.75
- ACTU $20.00
- AVG Volume (30 Days)
- ACRV 1.3M
- ACTU 73.5K
- Earning Date
- ACRV 05-13-2025
- ACTU 05-21-2025
- Dividend Yield
- ACRV N/A
- ACTU N/A
- EPS Growth
- ACRV N/A
- ACTU N/A
- EPS
- ACRV N/A
- ACTU N/A
- Revenue
- ACRV N/A
- ACTU N/A
- Revenue This Year
- ACRV N/A
- ACTU N/A
- Revenue Next Year
- ACRV N/A
- ACTU N/A
- P/E Ratio
- ACRV N/A
- ACTU N/A
- Revenue Growth
- ACRV N/A
- ACTU N/A
- 52 Week Low
- ACRV $1.30
- ACTU $5.51
- 52 Week High
- ACRV $10.29
- ACTU $11.73
- Technical
- Relative Strength Index (RSI)
- ACRV 29.23
- ACTU N/A
- Support Level
- ACRV $1.32
- ACTU N/A
- Resistance Level
- ACRV $1.50
- ACTU N/A
- Average True Range (ATR)
- ACRV 0.19
- ACTU 0.00
- MACD
- ACRV 0.06
- ACTU 0.00
- Stochastic Oscillator
- ACRV 2.08
- ACTU 0.00
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.